| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers O > Headlines for Oncolytics Biotech Inc. > News item |
Oncolytics' Reolysin reovirus finds and destroys cancer cells, study shows
By Angela McDaniels
Seattle, Dec. 5 -Oncolytics Biotech Inc. said preliminary study results indicate that Reolysin, Oncolytics' proprietary formulation of the human reovirus, showed evidence of virus replication within several types of tumors in patients who had failed all previous treatments and was well-tolerated.
The ongoing U.K. study was the first to show that the reovirus, a naturally occurring virus found in the environment, can seek out and destroy cancer cells in a variety of tumor types and locations when delivered intravenously to patients, the company said.
Of 12 patients who received doses of Reolysin on five consecutive days, at least four patients had stabilization of the measured tumor, the company said. Patients who experienced tumor activity included those with colorectal, prostate, non-small-cell lung and bladder cancers.
These early results showed that the reovirus, when delivered intravenously, enters cancer cells, replicates within them and ultimately kills them. It works by replicating within cancer cells that have an activated Ras pathway, a common mutation that is shared by roughly two thirds of all human cancers, the company said.
The results were presented by Johann S. de Bono of the Royal Marsden Hospital in London at the most recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.
Oncolytics has also started patient enrolment in a similar intravenous trial in the United States at the Montefiore Medical Center in New York City.
Calgary, Alta.-based Oncolytics was formed in 1998 to develop its proprietary product, Reolysin, as a potential therapeutic for a wide variety of human cancers.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.